594. Amsacrine

Nomenclature

CAS number: 51264-14-3
N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; 4′-(9-acridinylamino)methanesulfon-m-anisidide; m-AMSA; CI-880; NSC-249992; SN-11841; Amekrin (Warner-Lambert); Amsidine (Parke-Davis); Amsidyl (Pfizer).
C21H19N3O3S; mol wt 393.46.
C 64.10%, H 4.87%, N 10.68%, O 12.20%, S 8.15%.

Description and references

Cytostatic agent with antiviral and immunosuppressive properties. Prepn: B. F. Cain et al., J. Med. Chem. 18, 1110 (1975). Synthesis and biological properties of spin-labeled amsacrine: B. K. Sinha et al., ibid. 19, 994 (1976). Mechanism of action: W. R. Wilson, Chem. N. Z. 37, 148 (1973). Pharmacologic disposition: R. L. Cysyk et al., Drug Metab. Dispos. 5, 579 (1977). Antiviral activity: D. M. Byrd, Ann. N.Y. Acad. Sci. 284, 463 (1977). Immunosuppressive properties: B. C. Baguley et al., Eur. J. Cancer 10, 169 (1974). Exptl antitumor properties: B. F. Cain, G. J. Atwell, ibid. 539. Efficacy in adult acute leukemia: S. S. Legha et al., Ann. Intern. Med. 93, 17 (1980). Toxicologic studies: K. L. Pavkov et al., U.S. NTIS Report PB-298106 (1979) 284 pp, C.A. 92, 34335c (1980). Review of pharmacology and clinical efficacy: J. Hornedo, D. A. Van Echo, Pharmacotherapy 5, 78-90 (1985).

Chemical structure

Properties

LD50 in male, female CDF1 mice: 810 mg/m2; 729 mg/m2 orally (Pavkov).

Derivative

Hydrochloride.

Nomenclature

NSC-141549.
C21H19N3O3S.HCl; mol wt 429.92.
C 58.67%, H 4.69%, N 9.77%, O 11.16%, S 7.46%, Cl 8.25%.

Properties

Crystals, mp 197-199°. LD50 i.p. in mice: ≈60 mg/kg (Byrd).

Derivative

Methanesulfonate.

Nomenclature

NSC-156303.
C21H19N3O3S.CH3SO3H; mol wt 489.56.
C 53.97%, H 4.74%, N 8.58%, O 19.61%, S 13.10%.

Properties

Crystals, mp 292-293°. LD50 i.p. in mice: ≈24 mg/kg (Byrd).

Therapeutic Category

Antineoplastic.

Keywords

Antineoplastic; Topoisomerase II Inhibitor